Monotherapy with the oral androgen receptor inhibitor, enzalutamide, was associated with significant prostate-specific antigen response in men with hormone-naïve prostate cancer, found research presented at the 2013 Genitourinary Cancers Symposium.
Prostate-specific antigen testing detects a significant number of high- to intermediate-risk T1cN0M0 stage prostate cancers among African American men as well as elderly men of any race or ethnicity, according to research presented at the 2013 Genitourinary Cancers Symposium.
Surveillance is an option for older patients with small renal masses for whom surgery is unacceptable, according to research presented at the 2013 Genitourinary Cancers Symposium.
Dr. Neal Shore, MD, FACS, of Atlantic Urology Clinics shares his list of recommended abstracts that will be presented at the 2013 Genitourinary Cancers Symposium.
